Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alabama Neurology Associates PC

Neither a doctor nor a teaching hospital

Research payments

$1,506,841

85 payments

Through program year 2025, Alabama Neurology Associates PC is reported as receiving $1,506,841 in research payments, across 85 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,016,431 51
2024 Research $336,218 13
2022 Research $11,537 1
2021 Research $50,123 8
2020 Research $55,255 10
2019 Research $37,277 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genzyme Corporation $982,466 45 payments
  2. Novartis Pharmaceuticals Corporation $255,808 5 payments
  3. Sanofi US Services Inc. $122,689 16 payments
  4. Roche Products Limited $66,827 13 payments
  5. EMD Serono, Inc. $38,605 2 payments
  6. Biogen, Inc. $37,277 2 payments
  7. Mallinckrodt Hospital Products Inc. $3,168 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $513,393 28 payments
  2. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $469,073 17 payments
  3. A Pilot Open-Label, Randomized, Multi-Center, Parall El-Arm, of Acute VS Delay Ofatumumab Treatment D Uring An Acute Multiple Sclerosis Relapse $164,701 2 payments
  4. PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) $89,020 14 payments
  5. A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light $82,792 1 payment
  6. Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $66,827 13 payments
  7. The MS Leadership and Innovation Network (MS-LINK) Outcomes Study: A Comprehensive Prospective Longitudinal Assessment of Patient and Clinical Reported Outcomes in Multiple Sclerosis Patients across North America $38,605 2 payments
  8. A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment $21,685 1 payment
  9. Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) $18,670 1 payment
  10. Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants $15,592 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record